黑色素瘤是人类皮肤癌最具侵略性的形式之一，已经在研究中找寻最有效的治疗方式。对于早期诊断的初发性黑色素瘤，外科手术切除，对于晚期/转移性黑色素瘤则使用靶向疗法和免疫检查点抑制剂是最佳的临床方法。铁死亡途径（一种新发现的依赖于铁的细胞死亡途径，形态和生物化学不同于凋亡和坏死），已经被报道与多种癌症有关。铁死亡诱导剂可在晚期/转移性黑色素瘤对传统疗法产生耐药性时提供治疗选择。最近开发的铁死亡诱导剂，如MEK和BRAF抑制剂、miRNA如miR-137和miR-9，以及针对黑色素瘤主要组织相容性复合体（MHC）II的新策略，可以为黑色素瘤治疗提供新的机会。将铁死亡诱导剂与靶向疗法或免疫检查点抑制剂相结合，可以提高患者的反应率。本文回顾了铁死亡的机制及其环境触发因素。我们还讨论了黑色素瘤的发病机制和目前的治疗方法。此外，我们旨在阐明铁死亡与黑色素瘤之间的关系及铁死亡对黑色素瘤发展新的治疗策略的意义。版权所有©2023 Elsevier B.V.

Melanoma, the most aggressive form of human skin cancer, has been under investigation to reach the most efficient treatment. Surgical resection for early-diagnosed primary melanoma, targeted therapies, and immune checkpoint inhibitors for advanced/metastatic melanoma is the best clinical approach. Ferroptosis, a newly identified iron-dependent cell death pathway, which is morphologically and biochemically different from apoptosis and necrosis, has been reported to be involved in several cancers. Ferroptosis inducers could provide therapeutic options in case of resistance to conventional therapies for advanced/metastatic melanoma. Recently developed ferroptosis inducers, MEK and BRAF inhibitors, miRNAs such as miR-137 and miR-9, and novel strategies for targeting major histocompatibility complex (MHC) class II in melanoma can provide new opportunities for melanoma treatment. Combining ferroptosis inducers with targeted therapies or immune checkpoint inhibitors increases patient response rates. Here we review the mechanisms of ferroptosis and its environmental triggers. We also discuss the pathogenesis and current treatments of melanoma. Moreover, we aim to elucidate the relationship between ferroptosis and melanoma and ferroptosis implications to develop new therapeutic strategies against melanoma.Copyright © 2023 Elsevier B.V. All rights reserved.